Ranbaxy and EPIRUS to sign licensing agreement
For biosimilar product
Ranbaxy Laboratories and EPIRUS Switzerland GmBH have announced the signing of licensing agreement for BOW015, a biosimilar version of Infliximab.Powered by Capital Market - Live News
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 09 2014 | 10:58 AM IST